GLP-1s, first approved for type 2 diabetes in 2005, lower blood glucose, help avoid fatty liver disease, and help with obesity-related problems such as knee pain, sleep apnea, and gastroesophageal reflux
This does not necessarily mean tirzepatide is safer for the thyroid than semaglutide , as reporting biases, time on market, and user populations differ between the two medications
We launched Noom GLP-1 Rx to meet the needs of the market in the U.S
*Eligible patients without diabetes lost an average of 21% of their body weight (-48 lbs) in a 72-week clinical trial evaluating 15 mg tirzepatide, when paired with diet and exercise
This helped accommodate patients who could not, or chose not to, be seen in person at the height of covid transmission
P = 0.009 (for hsCRP) and 12.90 [25.98, 0.18] %